Neos Therapeutics Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Neos Therapeutics (NEOS) Tops Q1 EPS by 5c, Revenues Beat
May 9, 2019 7:14 AM EDTNeos Therapeutics (NASDAQ: NEOS) reported Q1 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $14.63 million versus the consensus estimate of $13.88 million.
We continued to make solid progress as we execute our new commercial strategy for our ADHD... More
